Table 3 Scores for Health-Related Quality of Life post GD2 specific 4SCAR-T cell infusion
From: Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma
Measure | Score | P Value | |
|---|---|---|---|
Prior to infusion | Post infusion | ||
QLQ-C30 | |||
 Global | 51.0 ± 7.4 | 62.9 ± 14.8 | 0.062 |
 Physical functioning | 64.4 ± 7.6 | 65.0 ± 6.8 | 0.864 |
 Role functioning | 64.1 ± 6.1 | 63.4 ± 10.9 | 0.868 |
 Emotional functioning | 66.8 ± 13.8 | 67.8 ± 11.8 | 0.878 |
 Cognitive functioning | 56.1 ± 8.9 | 66.8 ± 11.1 | 0.053 |
 Social functioning | 62.6 ± 8.8 | 62.3 ± 5.4 | 0.920 |
 Fatigue | 35.6 ± 8.8 | 28.8 ± 10.3 | 0.174 |
 Nausea and vomiting | 4.1 ± 2.1 | 3.8 ± 1.8 | 0.709 |
 Insomnia | 18.1 ± 2.5 | 22.8 ± 5.8 | 0.058 |
QLQ-b20 | |||
 Future uncertainty | 35.3 ± 5.6 | 29.6 ± 4.9 | 0.052 |
 Visual disorder | 18.3 ± 3.0 | 18.1 ± 2.5 | 0.929 |
 Motor dysfunction | 17.3 ± 2.4 | 19.3 ± 3.9 | 0.237 |
 Communication deficit | 21.5 ± 5.0 | 19.1 ± 3.6 | 0.295 |
 Bothered by hair loss | 5.8 ± 3.2 | 4.6 ± 2.9 | 0.468 |